BMO Capital Issues a Buy Rating on Pfizer

By Jason Carr

BMO Capital analyst Alex Arfaei assigned a Buy rating to Pfizer (NYSE: PFE) today and set a price target of $39. The company’s shares closed on Friday at $35.18.

According to, Arfaei is a 3-star analyst with an average return of 2.6% and a 52.5% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on Pfizer is Moderate Buy and the average price target is $39.89, representing a 13.4% upside.

In a report issued on October 31, Piper Jaffray also reiterated a Buy rating on the stock with a $54 price target.

Pfizer’s market cap is currently $209.2B and has a P/E ratio of 21.72. The company has a book value ratio of 3.5860.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.